ArticleNPJ precision oncology2025
Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02693535 (Targeted Agent and Profiling Utilization Registry), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Who cites it
1 citing paper in PubMed.
- Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Targeted Agent and Profiling Utilization (TAPUR) Study (NCT02693535, registered on February 23, 2016) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. We analyzed the prevalence of targetable gene alterations in the diverse population of patients participating in this study. We assessed 978 gene alterations or other biomarkers across sex, age, race, ethnicity, BMI category, smoking status, Eastern Cooperative Oncology Group performance status, and cancer type in 3448 registrants. We report a higher prevalence of genomic targets of FDA-approved therapies for various cancers, including PDGRFA in Hispanic versus non-Hispanic registrants and JAK2 in Asian versus White registrants. This study reinforces the importance of recruiting diverse populations of patients to clinical trials and provides evidence that may inform the development of strategic treatment plans that consider patient demographics in addition to tumor characteristics. Clinicaltrials.gov NCT02693535.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.